File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Temporal trends of the utilization patterns of sedative-hypnotic medications in children, adolescents and young adults: a 21-year population-based study with joinpoint regression analysis

TitleTemporal trends of the utilization patterns of sedative-hypnotic medications in children, adolescents and young adults: a 21-year population-based study with joinpoint regression analysis
Authors
KeywordsBenzodiazepines
Children & adolescents
Pharmacoepidemiology
Population-based
Prescribing trends
Z-drugs
Issue Date4-Feb-2025
PublisherBioMed Central
Citation
BMC Psychiatry, 2025, v. 25, n. 1 How to Cite?
AbstractBackground: There is limited research on real-world utilization patterns of benzodiazepines and Z-drugs (collectively-termed benzodiazepine-receptor agonists [BZRAs]) in children and adolescents, particularly in non-western countries. We aimed to examine temporal trends of BZRA prescribing-practice among children, adolescents and young adults in Hong Kong over a 21-year period. Methods: This population-based study identified 60,660 individuals aged 4–24 years who had redeemed ≥ 1 BZRA prescription within 2000–2020, using data from medical-record database of Hong Kong public-healthcare-services. We calculated annual prescription prevalence (per 1,000 persons per year) for any BZRA, BZRA-subtypes (short- and long-acting benzodiazepines, Z-drugs) and individual BZRAs. Joinpoint-regression analyses were performed to assess temporal BZRA prescription trends, quantified by average annual-percent-change (AAPC), with 95% confidence-intervals (CIs). Results: Overall BZRA prescription prevalence significantly increased (AAPC: 5.70% [95%CI: 5.31-6.54%]), from 1.88 in 2000 to 5.69 in 2020, uniformly across both sexes. Young adults (18–24 years-old) displayed the highest prescription prevalence, followed by adolescents (12–17 years-old) and children (4–11 years-old). Young adults and adolescents exhibited more pronounced increased BZRA use than children. Use of all BZRA subtypes consistently increased over time for all age-groups, except decline in Z-drug prescriptions in children. Lorazepam and diazepam represented the two most frequently-prescribed individual BZRAs, whereas alprazolam use showed the steepest increase. Anxiety and depression emerged as the most commonly-assigned diagnoses for BZRA-users. Conclusion: This first Asian population-based study indicates a significant rising trend of BZRA prescriptions, especially among adolescents and young adults. Judicious prescribing-practices and further investigation clarifying factors contributing to increased BZRA use are warranted.
Persistent Identifierhttp://hdl.handle.net/10722/355816
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKwok, Carltin Chun Ting-
dc.contributor.authorLo, Heidi Ka Ying-
dc.contributor.authorChan, Ching Yui-
dc.contributor.authorChan, Joe Kwun Nam-
dc.contributor.authorWong, Corine Sau Man-
dc.contributor.authorCheng, Calvin Pak Wing-
dc.contributor.authorHo, Chung-
dc.contributor.authorLeung, Brian Man Ho-
dc.contributor.authorWong, Wilfred Shone Horn-
dc.contributor.authorYu, Zoe Hoi Shuen-
dc.contributor.authorLee, Edwin Ho Ming-
dc.contributor.authorChang, Wing Chung-
dc.date.accessioned2025-05-17T00:35:16Z-
dc.date.available2025-05-17T00:35:16Z-
dc.date.issued2025-02-04-
dc.identifier.citationBMC Psychiatry, 2025, v. 25, n. 1-
dc.identifier.urihttp://hdl.handle.net/10722/355816-
dc.description.abstractBackground: There is limited research on real-world utilization patterns of benzodiazepines and Z-drugs (collectively-termed benzodiazepine-receptor agonists [BZRAs]) in children and adolescents, particularly in non-western countries. We aimed to examine temporal trends of BZRA prescribing-practice among children, adolescents and young adults in Hong Kong over a 21-year period. Methods: This population-based study identified 60,660 individuals aged 4–24 years who had redeemed ≥ 1 BZRA prescription within 2000–2020, using data from medical-record database of Hong Kong public-healthcare-services. We calculated annual prescription prevalence (per 1,000 persons per year) for any BZRA, BZRA-subtypes (short- and long-acting benzodiazepines, Z-drugs) and individual BZRAs. Joinpoint-regression analyses were performed to assess temporal BZRA prescription trends, quantified by average annual-percent-change (AAPC), with 95% confidence-intervals (CIs). Results: Overall BZRA prescription prevalence significantly increased (AAPC: 5.70% [95%CI: 5.31-6.54%]), from 1.88 in 2000 to 5.69 in 2020, uniformly across both sexes. Young adults (18–24 years-old) displayed the highest prescription prevalence, followed by adolescents (12–17 years-old) and children (4–11 years-old). Young adults and adolescents exhibited more pronounced increased BZRA use than children. Use of all BZRA subtypes consistently increased over time for all age-groups, except decline in Z-drug prescriptions in children. Lorazepam and diazepam represented the two most frequently-prescribed individual BZRAs, whereas alprazolam use showed the steepest increase. Anxiety and depression emerged as the most commonly-assigned diagnoses for BZRA-users. Conclusion: This first Asian population-based study indicates a significant rising trend of BZRA prescriptions, especially among adolescents and young adults. Judicious prescribing-practices and further investigation clarifying factors contributing to increased BZRA use are warranted.-
dc.languageeng-
dc.publisherBioMed Central-
dc.relation.ispartofBMC Psychiatry-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectBenzodiazepines-
dc.subjectChildren & adolescents-
dc.subjectPharmacoepidemiology-
dc.subjectPopulation-based-
dc.subjectPrescribing trends-
dc.subjectZ-drugs-
dc.titleTemporal trends of the utilization patterns of sedative-hypnotic medications in children, adolescents and young adults: a 21-year population-based study with joinpoint regression analysis-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1186/s12888-025-06515-x-
dc.identifier.pmid39905359-
dc.identifier.scopuseid_2-s2.0-85217983870-
dc.identifier.volume25-
dc.identifier.issue1-
dc.identifier.eissn1471-244X-
dc.identifier.isiWOS:001414308100001-
dc.identifier.issnl1471-244X-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats